Risk stratification in hypertrophic cardiomyopathy: Fact or fiction?

Journal of the American College of Cardiology

Volumn 42, Issue 5, 2003, Pages 880-881

  Hess, Otto M ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD PRESSURE; EXERCISE TEST; FAMILY HISTORY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SUDDEN DEATH; SYNCOPE;

EID: 0042866047     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00838-6     Document Type: Editorial

References (7)

1. Chien KR. Genomic circuits and the integrative biology of cardiomyopathies. Eur Heart J 2001;3:L3-9.
2. Watkins H. Hypertrophic cardiomyopathy: from molecular and genetic mechanisms to clinical management. Eur Heart J 2001;3:L43-50.
3. Janse MJ, De Bakker JMT. Arrhythmia substrate and management in hypertrophic cardiomyopathy: from molecules to implantable cardioverter-defibfillators. Eur Heart J 2001;3:L15-20.
4. Vassalli G, Seiler C, Hess OM. Risk stratification in hypertrophic cardiomyopathy. Curr Opin Cardiol 1994;9:330-6.
5. McKenna WJ, Rehr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 2002;87:169-76.
6. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73.
7. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:873-9.